Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03059147
Recruitment Status : Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : August 14, 2019
Sponsor:
Collaborator:
University of California, San Diego
Information provided by (Responsible Party):
SignalRX Pharmaceuticals, Inc.

Brief Summary:

Primary Objectives:

  1. To determine the maximum tolerated dose (MTD) or maximum recommended dose of SF1126 in combination with nivolumab in adult patients with advanced (unresectable or metastatic) HCC and Child-Pugh A or Child-Pugh B7 cirrhosis.
  2. To determine the recommended phase II dose of SF1126 in combination with nivolumab in patients with advanced (unresectable or metastatic) HCC and Child-Pugh A or Child-Pugh B7 cirrhosis.

Secondary Objectives:

  1. To describe the safety and tolerability of SF1126 in adult patients with underlying liver disease by ongoing evaluation of adverse events.
  2. To determine pharmacokinetics in HCC patients.
  3. To assess the effect of SF1126 in combination with nivolumab on progression-free survival and overall survival.

Primary Endpoint:

The primary endpoint is the rate of dose limiting toxicities (DLTs) at within 56 days of starting treatment, and the maximum tolerated dose or maximum recommended dose of SF1126 in combination with nivolumab.

Secondary Endpoints:

  1. Adverse events related to SF1126 (description, timing, grade [CTCAE v4.03], severity, seriousness, and relatedness).
  2. Pharmacokinetics in HCC patients.
  3. The proportion of patients remaining progression-free by radiographic criteria as assessed by RESIST v1.1 at 4 months, and, as available, median progression-free survival and overall survival estimated using the Kaplan-Meier method.

Condition or disease Intervention/treatment Phase
Advanced Hepatocellular Carcinoma Drug: SF1126 Drug: Nivolumab Phase 1

Detailed Description:

SF1126 is a dual inhibitor of phosphatidylinositol-3-kinase (pan-isoform specific) and bromodomain-containing protein 4 (BRD4) which simultaneously disrupts two key MYC-mediating factors that promote cancer cell growth.

Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. Nivolumab monotherapy is approved in the US for HCC previously treated with sorafenib.

Funding source: FDA OOPD


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Intervention Model: Single Group Assignment
Intervention Model Description: 3 + 3 Designed Phase I study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Combination With Nivolumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis
Actual Study Start Date : March 27, 2017
Actual Primary Completion Date : April 22, 2019
Estimated Study Completion Date : October 1, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: SF1126 + Nivolumab
SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
Drug: SF1126
SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.

Drug: Nivolumab
Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.




Primary Outcome Measures :
  1. Rate of dose limiting toxicities [ Time Frame: Occurring within 56 days of investigational treatment ]
    A dose limiting toxicity is a clinically significant adverse event (AE) occurring within 56 days of investigational treatment that is considered by the investigator to be possibly, probably, or definitely related to SF1126


Secondary Outcome Measures :
  1. Treatment-emergent adverse events [ Time Frame: 3 years ]
    To describe treatment-emergent adverse events (description, timing, grade [CTCAE v4.03], severity, seriousness, and relatedness)

  2. Peak plasma concentration (Cmax) [ Time Frame: 3 years ]
    Collection of plasma samples for SF1126 Cmax studies is required during cycle 1 for all patients during both the dose escalation and expansion cohort phases of the study

  3. Area under the plasma concentration versus time curve (AUC) [ Time Frame: 3 years ]
    Collection of plasma samples for SF1126 AUC studies is required during cycle 1 for all patients during both the dose escalation and expansion cohort phases of the study

  4. Progression-free survival [ Time Frame: 4 months ]
    The proportion of patients who remain progression free (according to RECIST1.1) after 4 months on study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To qualify for enrollment, all of the following criteria must be met:

  1. Willing and able to provide written informed consent prior to performance of any study-specific procedures.
  2. Age ≥ 18 years.
  3. Histological or radiologic diagnosis of advanced (unresectable or metastatic) HCC with Child-Pugh A or Child-Pugh B7 cirrhosis:

    1. The diagnosis of HCC will be made according to the European Association for the Study of the Liver-European Organization for Research and Treatment of Cancer Clinical Practice Guidelines (EASL EASL-EORTC CPG) and according to successive modifications of the American Association for the Study of Liver Disease (AASLD) practice guidelines.
    2. Pathological diagnoses of HCC will be made according to the International Working Party criteria.
  4. Is not a candidate for local therapies, including liver transplantation, tumor ablation, transarterial embolization, or resection.
  5. No known FDA-approved therapy available that is expected to prolong survival by greater than 3 months.
  6. ECOG Performance Status ≤ 2.
  7. Has measurable or evaluable disease as per RECIST v1.1.
  8. Life expectancy of ≥ 12 weeks.
  9. Has recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy:

    • Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea)
    • Biologic (anti-neoplastic agent): At least 7 days since completion of therapy with a biologic agent.
    • Radiation (XRT): ≥ 1 week must have elapsed from prior palliative XRT to non-target lesions.
  10. Inability to tolerate first-line treatment with sorafenib (e.g., unacceptable toxicity), tumor progression on sorafenib, patient preference to stop sorafenib and for alternative therapy/trial, or patient preference to forgo sorafenib for alternative therapy/trial.
  11. Adequate Bone Marrow Function Defined for all subjects (including status post SCT):

    • Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3
    • Platelet count ≥ 50,000/mm3
    • Hemoglobin ≥ 8.0 g/dL (may receive transfusions)
  12. Adequate Renal Function Defined As:

    • Serum creatinine ≤ 1.5 x institution's ULN (upper limit of normal), or
    • Creatinine clearance ≥ 50 ml/min
  13. Adequate Liver and Pancreatic Function Defined As:

    • Total bilirubin ≤ 2.0 x upper limit of normal, and
    • ALT or AST ≤ 5 x upper limit of normal, and
    • Albumin ≥ 2 g/dL
  14. Adequate Central Nervous System Function Defined As:

    • Subjects with seizure disorder may be enrolled if on anticonvulsants and seizures are well controlled.
  15. Female subjects are eligible to enter the study if they are either:

    1. Of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who:

      • Has had a hysterectomy, or
      • Has had a bilateral oophorectomy, or
      • Has had a bilateral tubal ligation, or
      • Is post-menopausal (demonstrates total cessation of menses for greater than or equal to 1 year).

      OR

    2. Of childbearing potential, has a negative serum pregnancy test at screening, and agrees to one of the following contraceptives:

      • An intrauterine device (IUD) with a documented failure rate of less than 1% per year.
      • Vasectomized partner who is sterile prior to the subject's entry and is the sole sexual partner for that woman.
      • Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, during the clinical trial, and for at least 14 days after the last dose of investigational product.
      • Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.
  16. Male patients with partners of childbearing potential must agree to use adequate contraception while on study

Exclusion Criteria:

  1. Brain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before study entry, and stable without steroid treatment for at least 4 weeks.
  2. Evidence of severe or uncontrolled systemic diseases [e.g., unstable or uncompensated respiratory, cardiac (including life threatening arrhythmias)].
  3. Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy except alopecia (if applicable) unless agreed that the patient can be entered after discussion with the Medical Monitor.
  4. Presence of cardiac impairment defined as:

    • QTc prolongation defined as QTc ≥ 480 ms by ECGs; OR
    • prior history of cardiovascular disease including heart failure that meets New York Hearth Association (NYHA) class III and IV definitions; OR
    • history of myocardial infarction/active ischemic heart disease within one year of study entry; OR
    • uncontrolled dysrhythmias; OR
    • poorly controlled angina.
  5. Participation in a trial of an investigational agent within the prior 30 days.
  6. Pregnant or breast-feeding females.
  7. High volume peritoneal or pleural effusions requiring a tap more frequently than every 14 days. Moderate to severe ascites.
  8. Poorly controlled or refractory (grade 3-4) hepatic encephalopathy.
  9. History of other malignancies except curatively excised carcinoma in situ of the cervix, non-melanoma skin cancer or superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for ≥ 5 years. Other cases will be reviewed and possibly allowed if discussed with and approved by Medical Monitor.
  10. Patients receiving therapeutic doses of warfarin. Lovenox is permitted.
  11. Criteria for hypertension: Blood pressure greater than 170/90 or 2 SD from normal based on age and weight nomogram on 3 separate measurements. Uncontrolled HTN.
  12. Any concurrent condition which in the investigator's opinion makes it undesirable for the subject to participate in this trial or which would jeopardize compliance with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03059147


Locations
Layout table for location information
United States, California
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
SignalRX Pharmaceuticals, Inc.
University of California, San Diego

Additional Information:
Layout table for additonal information
Responsible Party: SignalRX Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03059147     History of Changes
Other Study ID Numbers: 161007
FD-05113 ( Other Grant/Funding Number: FDA OOPD )
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: August 14, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents